CervoMed (CRVO)
NASDAQ:CRVO
Want to see CRVO full AI Analyst Report?
Top Page
CervoMed
(NASDAQ:CRVO)
Select Model
Select Model
Rating:44Neutral
Price Target:
$3.00
▼(-24.62% Downside)
Action:Reiterated
Date:05/19/26
The score is held down primarily by weak financial performance (minimal revenue, large losses, and heavy cash burn) and bearish technicals (price below key moving averages with weak momentum). Positive clinical/program progress in recent corporate events provides some offset, but valuation metrics are not supportive due to ongoing losses and no dividend.
Positive Factors
Positive Phase 2b biomarker & MRI data
Placebo-controlled MRI and biomarker findings provide mechanistic, disease-relevant evidence that neflamapimod affects basal forebrain atrophy and functional connectivity in DLB. This durable scientific signal supports a biomarker-driven trial design and increases the plausibility of meaningful clinical benefit in later-stage studies.
Negative Factors
Minimal and declining revenue
A near-zero and sharply falling revenue base shows the company lacks recurring commercial income to offset R&D and G&A. Over the medium term this limits self-funding ability, increases reliance on capital markets, and makes sustaining multi-indication clinical programs dependent on financing rather than operating cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive Phase 2b biomarker & MRI data
Placebo-controlled MRI and biomarker findings provide mechanistic, disease-relevant evidence that neflamapimod affects basal forebrain atrophy and functional connectivity in DLB. This durable scientific signal supports a biomarker-driven trial design and increases the plausibility of meaningful clinical benefit in later-stage studies.
Read all positive factors
CervoMed (CRVO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$29.07M
Dividend YieldN/A
Average Volume (3M)112.80K
Price to Earnings (P/E)―
Beta (1Y)-0.08
Revenue Growth-77.56%
EPS Growth-50.38%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.27
Shares Outstanding9,258,719
10 Day Avg. Volume143,994
30 Day Avg. Volume112,798
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.92
Price to Sales (P/S)0.00
P/FCF Ratio-3.05
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue65.51
Enterprise Value/Gross Profit65.51
Enterprise Value/Ebitda-0.69
Forecast
1Y Price Target
$20.40Price Target Upside412.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.7
Revenue Forecast (FY)$357.14K
CervoMed Business Overview & Revenue Model
Company Description
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the trea...
How the Company Makes Money
As a clinical-stage biotechnology company, CervoMed does not typically generate recurring product revenue and primarily funds operations through capital-raising activities. Based on publicly available high-level information, specific, itemized rev...
CervoMed Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 322.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 322.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -30.78M | -28.29M | -18.23M | -7.81M | -5.80M | -15.94M |
| Net Income | -30.04M | -26.97M | -16.29M | -2.17M | -5.80M | -24.10M |
Balance Sheet | ||||||
| Total Assets | 15.11M | 23.40M | 43.08M | 9.97M | 4.16M | 37.84M |
| Cash, Cash Equivalents and Short-Term Investments | 12.92M | 20.86M | 38.92M | 7.79M | 4.09M | 37.31M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 12.41M | 0.00 |
| Total Liabilities | 4.50M | 5.18M | 3.88M | 2.60M | 13.16M | 2.93M |
| Stockholders Equity | 10.62M | 18.22M | 39.20M | 7.38M | -9.00M | 34.91M |
Cash Flow | ||||||
| Free Cash Flow | -27.57M | -23.45M | -16.53M | -7.45M | -2.57M | -14.50M |
| Operating Cash Flow | -27.57M | -23.45M | -16.53M | -7.45M | -2.57M | -14.50M |
| Investing Cash Flow | 20.41M | 18.10M | -28.66M | 0.00 | 0.00 | 4.00K |
| Financing Cash Flow | 4.60M | 4.59M | 46.40M | 11.15M | 0.00 | 33.30M |
CervoMed Technical Analysis
Negative
3.98
Price Trends
3.73
Negative
4.54
Negative
6.47
Negative
Market Momentum
-0.23
Positive
37.02
Neutral
35.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRVO, the sentiment is Negative. The current price of 3.98 is above the 20-day moving average (MA) of 3.44, above the 50-day MA of 3.73, and below the 200-day MA of 6.47, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 37.02 is Neutral, neither overbought nor oversold. The STOCH value of 35.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRVO.
CervoMed Risk Analysis
CervoMed disclosed 75 risk factors in its most recent earnings report. CervoMed reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CervoMed Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $313.01M | -4.16 | -118.24% | ― | 138.86% | 42.14% | |
50 Neutral | $390.48M | -5.46 | -94.90% | ― | -71.26% | -300.04% | |
46 Neutral | $36.66M | -3.81 | -70.28% | ― | -100.00% | -170.04% | |
45 Neutral | $24.93M | -0.29 | -191.12% | ― | ― | 38.53% | |
44 Neutral | $29.07M | -0.96 | -136.08% | ― | -77.56% | -50.38% |
* Healthcare Sector Average
CRVO
CervoMed
3.11
-5.05
-61.89%
XFOR
X4 Pharmaceuticals
4.31
0.50
13.12%
ABVC
ABVC BioPharma
1.41
-0.13
-8.44%
JSPR
Jasper Therapeutics
0.83
-4.62
-84.79%
PRLD
Prelude Therapeutics
3.92
3.01
330.77%
ESLA
Estrella Immunopharma
1.09
0.12
12.37%
CervoMed Corporate Events
Business Operations and StrategyFinancial Disclosures
CervoMed Highlights Q1 Results and Neflamapimod Progress
Neutral
May 18, 2026
CervoMed reported first-quarter 2026 results on May 18, 2026, highlighting continued progress with its lead candidate neflamapimod across multiple neurodegenerative indications. The company completed Phase 3 trial design for dementia with Lewy bod...
Business Operations and Strategy
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results
Positive
Apr 22, 2026
On April 22, 2026, CervoMed reported Phase 2b RewinD-LB trial data presented at the American Academy of Neurology meeting showing that neflamapimod increased basal forebrain volume and enhanced functional connectivity in patients with dementia wit...
Business Operations and StrategyProduct-Related Announcements
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
Positive
Apr 7, 2026
On April 7, 2026, CervoMed announced that its representatives would present key aspects of the neflamapimod clinical program at the 2026 Lewy Body Dementia Association Annual Meeting in Atlanta, highlighting clinical findings, global regulatory al...
Business Operations and StrategyRegulatory Filings and Compliance
CervoMed Posts Investor Presentation Under Regulation FD Disclosure
Neutral
Mar 23, 2026
CervoMed Inc. has posted an investor presentation on its website under the Investors – Events and Presentations section, outlining summary information about its business, clinical studies, development plans and financial position intended to...
Business Operations and Strategy
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
Positive
Mar 19, 2026
On March 19, 2026, CervoMed reported new analyses from its Phase 2b RewinD-LB trial showing that DLB patients with lower plasma pTau181 levels, indicating absence of Alzheimer’s co-pathology and earlier-stage disease, experienced greater cli...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
CervoMed Reports 2025 Results, Advances Neflamapimod Programs
Neutral
Mar 17, 2026
On March 17, 2026, CervoMed reported fourth quarter and full-year 2025 results alongside updates on its neflamapimod pipeline, highlighting positive Phase 2b RewinD-LB data in dementia with Lewy bodies presented in 2025 and regulatory alignment wi...
Business Operations and StrategyProduct-Related Announcements
CervoMed Advances Neflamapimod With Phase 1 Completion
Positive
Mar 4, 2026
On March 4, 2026, CervoMed reported completion of a Phase 1 healthy volunteer study assessing the pharmacokinetics of a new, stable crystal form of its lead drug neflamapimod, manufactured via a controlled process to avoid prior polymorph-related ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.